Among
numerous posttranslational regulation patterns, phosphorylation
is reversibly controlled by the balance of kinases and phosphatases.
The major form of cellular signaling involves the reversible phosphorylation
of proteins on tyrosine, serine, or threonine residues. However, altered
phosphorylation levels are found in diverse diseases, including cancer,
making kinases and phosphatases ideal drug targets. In contrast to
the success of prosperous kinase inhibitors, design of small molecules
targeting phosphatase is struggling due to past bias and difficulty.
This is especially true for serine/threonine phosphatases, one of
the largest phosphatase families. From this perspective, we aim to
provide insights into serine/threonine phosphatases and the small
molecules targeting these proteins for drug development, especially
in cancer. Through highlighting the modulation strategies, we aim
to provide basic principles for the design of small molecules and
future perspectives for the application of drugs targeting serine/threonine
phosphatases.